Clinical Trial

Effects of Enamel Matrix Derivative in the Treatment of Peri-implant Mucositis

Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
To evaluate the naturally occurring peri-implant mucositis (PM) treatment by means of non-surgical sub-marginal peri-implant instrumentation (NSPI) with or without use of enamel matrix protein derivative (EMD). Specifically, the primary outcome of the present study compared the efficacy of NSPI +EMD with respect to NSPI and placebo in the treatment of PM at 6 months follow-up by means of BOP reduction. The secondary outcome evaluated the influence of possible predictors on the BOP changes among all follow-up sessions.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-05.
Trial Details
NCT Number NCT06725095
Lead Sponsor University of Catania
Conditions Mucositis, Peri Implant Mucositis
Enrollment 54 participants
Start Date 2024-12-05
Primary Completion 2025-02-01 (estimated)
Study Completion 2025-06-05 (estimated)
Updated on ClinicalTrials.gov 2025-06-04